anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Neuropathic pain (NP) is common (population prevalence of 7-8%) and will present a rising health burden in the future. NP arises as a consequence of a disease or lesion in the somatosensory nervous system. NP results in significant morbidity, reduces quality of life and has a major deleterious impact on health in aging. However, not everyone with such a lesion develops significant neuropathic pain, and those who do develop it include a wide range of severity, impact and outcomes, and an unpredictable response to evidence-based treatment. The reason why some subjects develop neuropathic pain and others do not following the same injury is not known. Genetic variants are increasingly recognized as being important in the development of neuropathic pain. There are a number of Mendelian primary neuropathic pain disorders which act as exemplars of high impact gene variants which have in a number of cases been shown to alter primary afferent excitability. In addition genetic factors are also likely to be important as risk factors in more common acquired (or secondary) neuropathic pain disorders. So, identifying these risk factors will have a significant impact on health both in identifying vulnerable patients and potential for developing new treatment modalities. The proposed study is a part of multicenter international project under Horizons 2020 program of the European Union. Our aim is to understand pain pathophysiology in terms of risk factors and protective mechanisms ranging from molecular pathways to societal impacts. The desired impact is to provide a firm platform to improve diagnosis and stratify patients according to risk profile, employ preventive strategies and ultimately develop novel therapeutics.

Specific objectives for the study at large will be to: 1) Identify the influence of demographic, environmental/societal and clinical factors on the risk of developing and maintenance of NP. 2) To apply modern genomics to validate (using a targeted approach) and find novel (using genome wide association) genetic risk factors for NP. 3) To determine if patient stratification using physiological (sensory profile, endogenous analgesic mechanisms and nerve excitability) and psychological factors can predict NP risk and progression. 4) Development of a risk model/algorithm for (severe) NP, combining measurable genetic and environmental factors. The desired impact is to provide a firm platform to improve diagnosis and stratify patients according to risk profile, employ preventive strategies and ultimately develop novel therapeutics.
For the duration of the 12 weeks, Healthy at Home will provide health coaching in 10-20 minute phone calls weekly. They will request daily blood glucose logs as this is part of Healthy at Home's normal procedure. The health coach and subject will choose a patient-directed overarching goal such as "lose weight," or improve my blood sugar numbers," etc. that the health coach will then help the patient turn into a SMART goal. They will do this by utilizing a list of lifestyle change categories as top priority goals from which to choose from in their patient-directed health coaching sessions. Texting will be utilized to request daily blood glucose and provide real-time coaching via text.
Lotrafilcon B contact lenses with EOBO-41 worn first, followed by lotrafilcon B contact lenses worn second. Both products worn bilaterally (in both eyes) for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
Radioactive cyclopentadienyl rhenium complexes of formula (I) are new. In (I) R1 and R2 = any substit. provided R1 and R2 are not both H; R2 = pref. H; Re = a radioactive rhenium isotope. Specifically substit. can be aliphatic chains, aromatic, hydroaromatic or heterocyclic gps.. USE/ADVANTAGE - (I) in which R1 = cOOH and R2 = COOH or H can be used either directly or in the form of an activated carboxylic acid deriv. for labelling proteins, esp. polyclonal or monoclonal antibodies. (I) can also be used in radiotherapy esp. of tumours. Depending on the choice of R substd. (I) can be tailored for the treatment of various tumours e.g. Re-186 cyrherenyl ethylnyl oestradiol enriches in tissues contg. oestrogen receptors and can therefore be used for the targetted radiotherapy of mammory tumour and the corresp. metastases. Previous rhenium complexes have only had very reduced possibilities for chemical variation, unlike (I) where many variations are possible. The rhenium complexes (I) are analagous to cymantrene and are hence called cyrhetrene.
Ifosfamide has been shown to require metabolic activation by microsomal liver enzymes to produce biologically active metabolites. Activation occurs by hydroxylation at the ring carbon atom 4 to form the unstable intermediate 4-hydroxyifosfamide. This metabolite rapidly degrades to the stable urinary metabolite 4-ketoifosfamide. Opening of the ring results in formation of the stable urinary metabolite, 4-carboxyifosfamide. These urinary metabolites have not been found to be cytotoxic. N, N- bis (2-chloroethyl)-phosphoric acid diamide (ifosphoramide) and acrolein are also found. Enzymatic oxidation of the chloroethyl side chains, and subsequent dealkylation produces the major urinary metabolites, dechloroethyl ifosfamide and dechloroethyl cyclophosphamide. The alkylated metabolites of ifosfamide have been shown to interact with DNA. 

In vitro incubation of DNA with activated ifosfamide has produced phosphotriesters. The treatment of intact cell nuclei may also result in the formation of DNA-DNA cross-links. DNA repair most likely occurs in G-1 and G-2 stage cells.
: Multiple Sclerosis (MS) is the most frequent disabling neurological disease in young adults. Over the past two decades, cognitive impairment in MS has received increasing interest. Although for a long time described in MS text books, it has been underestimated until recently. It is now accepted as an important feature of MS with a high impact on working and social abilities. The cognitive disorders in MS are dominated by a slowdown in information processing speed (IPS), as well as disturbances of attention and memory. The nature of cognitive findings suggest that the impairments depend on the integrity of large-scale cortical integrative processes, which involve long-distance white matter projections which can be impaired due to diffuse demyelinating injury in patients with MS. At the early stages of MS there is increasing evidence that neuroplasticity, the ability of the brain to respond to various insults, allows adaptive reorganization of cognitive functions to limit impairment, despite widespread tissue damage. Recently, we showed that at the early stages of RRMS compensatory capacities are relatively maintained, especially in highly-educated patients suggesting that cognitive training might be useful. The requirement of cerebral compensatory mechanisms to perform the cognitive tests was postulated in MS patients on the basis of functional MRI (fMRI) studies. By using a go/no go task of increasing complexity in a fMRI study in RRMS patients, we observed that a limitation of this compensatory cerebral recruitment appears when the attentional solicitations reach a particular level of difficulty. We postulate that a cognitive training program may help to maintain these compensatory capacities. Therefore, we propose to evaluate the effect of the program on brain activation using a task with several levels of attention requirement (increased attention load) by using fMRI and to evaluate in parallel its clinical effect and its impact in daily activities.
PROBLEM TO BE SOLVED: To provide a hair-coloring cosmetic that has high coloring power with extremely reduced secondary staining, gives soft and natural finish, moreover remains no color on the hair after shampooing and has excellent stability. SOLUTION: This hair-coloring cosmetic comprises an amphoteric polymer resin represented by formula (R1 and R6 are each H or methyl; R3 and R4 are each a 1-4C alkyl; R2 and R5 are each a 1-4C alkylene; R7 is a 1-24C alkyl where 15-100% of R7 is stearyl group; the cationization density of the amphoteric polymer resin is 0.3-0.8 and the average molecular weight of the polymer is 80,000-220,000), acidic dye and pigment. The amount of the amphoteric polymer resin is 0.01 - less than 1 wt.% based on the whole weight of the cosmetic, the amount of the acidic dye is 0.01 - less than 0.1 pt.wt. per 1 pt.wt. of the amphoteric resin and the amount of the pigment is 0.0005 - less than 1 pt.wt. per 1 pt.wt. of the total of the amphoteric polymer resin and the acidic dye.
Adderall® has a high potential for abuse and misuse. The use of Adderall® exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Adderall® can be diverted for non-medical use into illicit channels or distribution [see DRUG ABUSE AND DEPENDENCE: Abuse]. Misuse and abuse of CNS stimulants, including Adderall®, can result in overdose and death [see OVERDOSAGE], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing Adderall® assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store amphetamine sulfate in a safe place, preferably locked, and instruct patients to not give Adderall® to anyone else. Throughout Adderall® treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
Obesity condition causes morphological and functional alterations involving the cardiovascular system. These can represent the substrates for different cardiovascular diseases, such as atrial fibrillation, coronary artery disease, sudden cardiac death, and heart failure (HF) with both preserved ejection fraction (EF) and reduced EF. Different pathogenetic mechanisms may help to explain the association between obesity and HF including left ventricular remodelling and epicardial fat accumulation, endothelial dysfunction, and coronary microvascular dysfunction. Multi-imaging modalities are required for appropriate recognition of subclinical systolic dysfunction typically associated with obesity, with echocardiography being the most cost-effective technique. Therapeutic approach in patients with obesity and HF is challenging, particularly regarding patients with preserved EF in which few strategies with high level of evidence are available. Weight loss is of extreme importance in patients with obesity and HF, being a primary therapeutic intervention. Sodium-glucose co-transporter-2 inhibitors have been recently introduced as a novel tool in the management of HF patients. The present review aims at analysing the most recent studies supporting pathogenesis, diagnosis, and management in patients with obesity and HF.
BACKGROUND: Non-coding RNA (ncRNA) is a type of RNA that does not code for proteins and plays a crucial role in the onset, progression, diagnosis, and therapy of acute pancreatitis. However, bibliometric, and visual analyses of studies on acute pancreatitis and ncRNA are lacking. This study seeks to provide a bibliometric overview of the knowledge structure and research hotspots of ncRNA in the field of acute pancreatitis research.
MATERIALS AND METHODS: Literature search and collection of information in the field of ncRNA-related research in acute pancreatitis from 2000-2023 through the Web of Science Core Collection. Use CiteSpace and VOSviewer to visually analyze countries, institutions, authors, and keywords.
RESULTS: A total of 563 articles have been published in the field of ncRNA-related research in acute pancreatitis, and the number of publications in this field is gradually increasing. The largest number of publications was from China. Four clusters were produced by the co-occurrence cluster analysis of the top 89 keywords: studies of ncRNA in inflammation, autophagy, and apoptosis in acute pancreatitis; studies related to microRNA expression in pancreatic cancer among ncRNA; studies related to microRNAs as diagnostic and therapeutic markers in acute pancreatitis; and studies related to ncRNA in acute pancreatitis; The key words "injury," "pathway" and "extracellular vesicles" are the key words of emerging research hotspots.
CONCLUSION: In conclusion, ncRNA research in acute pancreatitis is an established discipline. Researchers can use the research hotspots and frontiers in this field as a guide for choosing their research direction.
Yi Jin Jing exercise three times per week for 12 weeks. Each exercise lasts an hour and consists of three fundamental Yijinjing exercises.
This is a phase I open-label, multi-center, dose escalation study in Japanese patients with CRPC or advanced BC. LFA102 will be administered intravenously once every 4 weeks during the study. All patients will remain on treatment until they meet the criteria for study discontinuation (e.g. disease progression, unacceptable toxicity, patient withdrawal) or study closure.

This study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of LFA102. Each cohort will enroll a minimum of 3 patients. A two-parameter Bayesian logistic regression model employing the escalation with overdose control principle will be used during the escalation phase for dose level selection and for determination of the MTD or RD.
Adsorbed vaccine meningococcal C (combined - CRM197) produced by the Foundation Ezequiel Dias (FUNED). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old). For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
The invention relates to a speckle-removing hairdressing method, and particularly relates to a conditioning and speckle-removing hairdressing method by means of traditional Chinese medicines in five steps (blood nourishing; qi lifting; menstruation regulating; speckle removing; and skin tendering. The method nourishes blood, lifts qi and regulates menstruation by applying traditional Chinese medicinal materials such as cassia twig, radix bupleurim, rhizoma polygonati, the roots of red-rooted salvia, rhizoma cyperi and a taohongsiwu decoction and meanwhile has the effect of acceleratedly removing speckles and tendering skins by applying fistular onion stalks, ginger and Chinese-date. Chromatodermatosis such as chloasma, cyasma, yellow skins and bad color are treated by nourishing blood, lifting qi and removing speckles. The color of face is remarkably bettered with 7-15 days, and the speckles are begin to dilute and are successfully removed within about two months. Compared with laser hairdressing, the method is free from damage to female skins, more durable and free from bounce. The color of skins can be remarkably improved and the gloss of the skins can be increased while the speckles are removed. A certain regulating effect to menstruation of female is further obtained.
Perfluorononanoic acid (PFNA), an acknowledged environmental endocrine disruptor, is increasingly utilized as a substitute for perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA). Despite its growing use, limited research has been conducted to investigate its potential impact on tumorigenesis and progression, and the potential molecular mechanisms. Earlier studies linked perfluoroalkyl and polyfluoroalkyl substances (PFAS) exposure to breast and gynecological cancer progression in humans, lacking a clear understanding of the underlying mechanisms, notably in ovarian cancer. Our investigation into PFNA's effects at environmental concentrations (0.25-2 mM) showed no significant impact on cell proliferation but a notable increase in invasion and migration of ovarian cancer cells. This led to alterations in epithelial-mesenchymal transition (EMT) markers, including Claudin1, Vimentin, and Snail. Notably, PFNA exposure activated the TGF-β/SMADs signaling pathway. Crucially, SMAD7 degradation through the ubiquitin-proteasome system emerged as PFNA's pivotal molecular target for inducing EMT, corroborated in mouse models. In summary, this study presented evidence that environmentally relevant concentrations of PFNA could induce SMAD7 degradation via the proteasome pathway, subsequently activating the TGF-β/SMADs signaling pathway, and promoting EMT in ovarian cancer. These results illuminated the association between PFNA exposure and metastasis of ovarian cancer.
Patients receive a continuous infusion containing a placebo solved in 50mL for up to 24 hours. Infusion will be started with surgical skin incision.
The invention relates to special-effect scapulohumeral periarthritis controlling tablets which are current novel products. Scapulohumeral periarthritis is a shoulder inflammation disease caused by wind, cold and dampness acting upon human bodies. The disease causes great pain on human bodies and great difficulties in working and studying. If the disease is not treated for a long time, partial paralysis can spread to arms, such that various pathologic symptoms such as arm numbness and muscle atrophy can be caused. The tablets are prepared from 18 Chinese herbal medicines such as incised notopterygium rhizome and root, Szechwan lovage rhizome, and the like. The tablets provide functions of rheumatism dispelling, meridian passage dredging, wind subduing and pain relieving. Therefore, if the tablets are taken by scapulohumeral periarthritis patients, substantial treatment effects can be provided.
D-VRd: Subjects will receive D-VRd for induction and consolidation followed by daratumumab and lenalidomide maintenance until disease progression or unacceptable toxicity. Minimal residual disease (MRD)-negative subjects in Arm B will stop therapy with daratumumab after sustained MRD negativity for 12 months and after a minimum of 24 months of maintenance therapy. These subjects will continue lenalidomide maintenance therapy until disease progression or unacceptable toxicity. After stopping daratumumab therapy, subjects with sustained MRD negativity should restart therapy with daratumumab if there is a recurrence of MRD or a confirmed loss of Complete Response (CR) without International Myeloma Working Group (IMWG)-defined disease progression. After reinitiating daratumumab, the subject will continue daratumumab and lenalidomide therapy until disease progression or unacceptable toxicity.
As a first step toward the overall goal of this project, the investigators will use data from T2 to conduct the first stage of a feasibility study. Specifically, the investigators will attempt to match Social Security numbers (SSNs) of Soldiers who have had suicidal thoughts and/or behaviors in the DoDSER against SSNs of Veterans seeking mental health services at any VA in the United States. Once this first step has been accomplished, the investigators also aim to describe the group of Veterans with DoDSERs who are accessing VA services (i.e., demographic information, military service variables, and health care utilization variables) in an attempt to better understand this group. It is anticipated that if this study is successful, a next step would be to explore the possibility of DoDSER data sharing with VA partners toward attainment of the following long-term goals: 1. Sharing information on history of active duty suicidal thoughts and/or behaviors among discharged individuals seeking mental health services in VA systems; 2. Facilitating identification of these Veterans; 3. Reducing VA clinician burden though effective access to existing data that may help in assessment and treatment planning; 4. Lowering health care costs through effective early management; 5. Improving quality of care for Veterans seeking services through VA outpatient mental health clinics.
A biologically-active polymeric medical composition (variants) relates to medicine, in particular, to medical compounds. According to the first variant the biologically-active polymeric medical composition comprises 3-hydroxybutyrate and 3-hydroxyvalerate (3-PHB/3-PHV) copolymer, and, at least, one biologically active substance and a solvent, a novel feature is characterized in that it comprises a biologically active substance selected from a group of antibiotics comprising gentamicin, tienam, rifampicin, vancomycin or nonsteroid anti-inflammatory preparations in the following proportions, wt %: 3-PHB/3-PHV copolymer 1-6; biologically active substance 1-5; solvent the rest. According to the second variant the biologically-active polymeric medical composition comprises a biologically active substance selected from a group of antibiotics or nonsteroid anti-inflammatory preparations and further comprises a surfactant. According to the third variant the biologically-active polymeric medical composition comprises a biologically active substance selected from a group of antibiotics or nonsteroid anti-inflammatory preparations and further comprises a polyethylene glycol. According to the fourth variant the biologically-active polymeric medical composition comprises a biologically active substance selected from a group of antibiotics or nonsteroid anti-inflammatory preparations and further comprises a gelatin. The technical result provides creation of the biologically active polymeric medical composition of wide spectrum of action and application showing biological compatibility and hematological compatibility, optimal physical-chemical properties, as well as an ability for slow biological resorption in vivo with making no toxic products and negative reactions during use thereof.
The present invention relates to a composition for alleviating cognitive impairment, reduced learning ability or reduced memory ability due to degenerative brain diseases, including a fermented extract of Perilla frutescens britton var. acuta kudo, and a fiber or flavor composition. In addition, the present invention relates to a composition for preventing, alleviating or treating cognitive impairment, reduced learning ability or reduced memory ability due to degenerative brain diseases, including a fermented extract of Perilla frutescens britton var. acuta kudo. The fermented extract of Perilla frutescens britton var. acuta kudo of the present invention significantly enhances cognitive ability or memory ability compared to a non-fermented extract of Perilla frutescens britton var. acuta kudo, and thus can be effectively used as a composition for preventing, alleviating or treating cognitive impairment, reduced learning ability or reduced memory ability due to degenerative brain diseases.
Each volunteer will receive a single dose of simvastatin on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 2 through 6. On Day 7 volunteers will receive a single dose of simvastatin in combination with a single dose of canagliflozin.
The present invention discloses a medicinal plaster stroma which is suitable for various plaster carriers and comprises terpene resin, polyvinyl alcohol, dibutyl phthalate, polyvinyl chloride, zinc oxide, camphor, etc. which are mixed and refined into a plaster according to a certain proportion and a method. The medicinal plaster stroma has the advantages of simple preparation technology and stable quality, and can be used as a carrier for all kinds of lipophilic and hydrophilic pasty medicine or fine powder medicine so that medicine performs the functions of high efficiency, quick effect and long-lasting effect. The medicinal plaster stroma does not have allergy or stimulation to skin, or saturnism danger or clothes pollution. Before being used, the present invention is not preheated and softened. The present invention makes a user comfortable by applying the medicinal plaster stroma, and is an ideal substitute product for a black plaster, a rubber plaster and a Braun preparation plaster.